Micelle-Associated Protein in Epoetin Formulations: A Risk Factor for Immunogenicity?
- 1 December 2003
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 20 (12) , 1903-1907
- https://doi.org/10.1023/b:pham.0000008034.61317.02
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Pharmaceutical biotechnology products approved within the European UnionEuropean Journal of Pharmaceutics and Biopharmaceutics, 2003
- Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and PredictionCurrent Pharmaceutical Biotechnology, 2002
- Uncertainties − discrepancies in immunologyImmunological Reviews, 2002
- Bioequivalence and the immunogenicity of biopharmaceuticalsNature Reviews Drug Discovery, 2002
- Antibodies against rHuEPO: native and recombinant.Nephrology Dialysis Transplantation, 2002
- Drug-Induced Autoimmune Red-Cell AplasiaNew England Journal of Medicine, 2002
- Interferon immunogenicity: technical evaluation of interferon-alpha 2a.1997
- Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic MicePharmaceutical Research, 1997
- Role of Aggregated Human Growth Hormone (hGH) in Development of Antibodies to hGH*Journal of Clinical Endocrinology & Metabolism, 1980
- CMC of PolysorbatesJournal of Pharmaceutical Sciences, 1974